• Recruiting

NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma

Updated: Sep 29

Talquetamab Phase 2

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Talquetamab

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed & Refractory Multiple Myeloma


The purpose of this study is to evaluate the efficacy of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).

TALMMY1001-Part 3

The corresponding study (NCT03399799) is the Phase 1 part of the study and TALMMY1001- Part 3 is the Phase 2 part of the study.

 

Sponsor

Janssen Research & Development, LLC

 

ClinicalTrials.gov Identifier: NCT04634552

Official Title: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

First Posted : November 18, 2020

Click here to see details on ClinicalTrials.gov

 

Drug: Talquetamab

JNJ-64407564 - Talquetamab

bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D)

JNJ 64407564

 

- Arkansas: University of Arkansas Little Rock

- Alabama: University of Alabama at Birmingham

- California: City of Hope Duarte

- Georgia: Emory University Atlanta

- Illinois: University of Chicago

- Missouri: Washington University School of Medicine Saint Louis

- New York: Tisch Cancer Institute Mount Sinai Hospital New York

- New York: NYU Langone Medical Center New York

- New York: University of Rochester New York

- North Carolina: Levine Cancer Institute Charlotte

- Tennessee: Sarah Cannon Research Institute Nashville

 

Locations

United States, Alabama

United States, Arizona

United States, Arkansas

United States, California

United States, Georgia

United States, Illinois

United States, Kentucky

United States, Michigan

United States, Missouri

United States, New York

United States, North Carolina

United States, Ohio

United States, Oregon

United States, Tennessee

United States, Texas


Europe

France

Germany

Netherlands

Spain

Belgium

Poland

Asia

Israel

Japan

Korea, Republic of

China

 

RELATED POSTS

TECLISTAMAB STUDIES:


NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma (MajesTEC1)

Click here for details


NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)

Click here for details


NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - (MajesTEC-3)

Click here for details


NCT05243797: Phase 3: Tec + Len Vs Len Alone in NDMM as Maintenance Therapy Post ASCT (MajesTEC-4)

Click here for details


NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma

Click here for details


NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)

Click here for details

 

TALQUETAMAB STUDIES:


NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1

Click here for details


NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma

Click here for details


NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma

Click here for details

 

TECLISTAMAB AND TALQUETAMAB STUDIES:


NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma

Click here for details


NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2

Click here for details



Posts Archive